Systemic and intrahepatic interferon‐gamma‐inducible protein 10 kDa predicts the first‐phase decline in hepatitis C virus RNA and overall viral response to therapy in chronic hepatitis C

摘要: High systemic levels of interferon-gamma-inducible protein 10 kDa (IP-10) at onset combination therapy for chronic hepatitis C virus (HCV) infection predict poor outcome, but details regarding the impact IP-10 on reduction HCV RNA during remain unclear. In present study, we correlated pretreatment in liver biopsies (n = 73) and plasma 265) with throughout within a phase III treatment trial (DITTO-HCV). Low or intrahepatic were strongly associated pronounced first 24 hours all patients (P < 0.0001 P 0.002, respectively) as well when grouped genotype 1 4 0.0008 0.01) 2 3 0.02). also predictive absolute 0.0001) maximum days sustained virological response (genotype 1/4; 0.0001). To corroborate relationship between early viral decline IP-10, samples from an independent IV genotypes 2/3 (NORDynamIC trial; n 382) analyzed. The results confirmed association immediate to 0.006). contrast, did not affect 8 29, i.e., second-phase decline, later time points any these cohorts. Conclusion: C, low favorable first-phase pegylated interferon ribavirin HCV. (HEPATOLOGY 2010.)